Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

NAMS

NewAmsterdam Pharma Company NV

May 13 • 04:00PM ET

37.75

-1.14 -2.93 %

Healthcare • Biotechnology • Netherlands • Mid • NASD

Peers: BBIO CYTK MDGL VKTX MLTX

| Held by: CGMM IBB SBIO VHT FFSM FYC ONEQ ESML MSSM FHLC

Index	-	P/E	-	EPS (ttm)	-1.80	Insider Own	36.51%	Shs Outstand	116.64M	Perf Week	21.81%
Market Cap	4.41B	Forward P/E	-	EPS next Y	-1.39	Insider Trans	-3.55%	Shs Float	74.23M	Perf Month	9.61%
Enterprise Value	3.78B	PEG	-	EPS next Q	-0.48	Inst Own	67.64%	Short Float	10.62%	Perf Quarter	10.25%
Income	-212.73M	P/S	195.53	EPS this Y	-4.95%	Inst Trans	1.93%	Short Ratio	7.43	Perf Half Y	-3.13%
Sales	22.57M	P/B	6.62	EPS next Y	22.82%	ROA	-27.43%	Short Interest	7.88M	Perf YTD	7.61%
Book/sh	5.70	P/C	6.92	EPS next 5Y	45.84%	ROE	-29.49%	52W High	42.21 -10.56%	Perf Year	101.33%
Cash/sh	5.45	P/FCF	-	EPS past 3/5Y	-12.98% -	ROIC	-31.98%	52W Low	16.78 124.90%	Perf 3Y	190.38%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-39.71% -	Gross Margin	98.98%	Volatility	10.58% 6.64%	Perf 5Y	283.64%
Dividend TTM	-	EV/Sales	167.29	EPS Y/Y TTM	3.91%	Oper. Margin	-953.59%	ATR (14)	2.28	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.76	Sales Y/Y TTM	-52.13%	Profit Margin	-942.76%	RSI (14)	64.34	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	9.76	EPS Q/Q	-16.92%	SMA20	15.73%	Beta	0.07	Target Price	51.21
Payout	-	Debt/Eq	0.00	Sales Q/Q	2.08%	SMA50	17.92%	Rel Volume	1.65	Prev Close	38.89
Employees	100	LT Debt/Eq	0.00	Earnings	May 07 BMO	SMA200	17.33%	Avg Volume	1.06M	Price	37.75
IPO	Feb 08, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.38% 72.87%	Trades		Volume	1,749,737	Change	-2.93%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-26	Initiated	Truist	Buy	$57
Oct-20-25	Resumed	H.C. Wainwright	Buy	$52
Aug-25-25	Initiated	Wells Fargo	Overweight	$45
Jul-17-25	Initiated	Goldman	Neutral	$27
Jun-17-25	Initiated	Citigroup	Buy	$42
Jun-10-25	Initiated	Stifel	Buy	$44
Jun-04-25	Initiated	Cantor Fitzgerald	Overweight	$42
Dec-30-24	Initiated	H.C. Wainwright	Buy	$48
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform	$35
Jan-18-24	Initiated	Guggenheim	Buy	$30
Jan-16-24	Initiated	Piper Sandler	Overweight	$37
Oct-30-23	Initiated	RBC Capital Mkts	Outperform	$25

Show Previous Ratings

May-11-26 08:41AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May (GlobeNewswire)
May-07-26 07:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results (GlobeNewswire) +12.46%
May-01-26 04:57PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.03%
Apr-08-26 08:00AM	NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-02-26 05:43PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Mar-23-26 08:00AM	NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session (GlobeNewswire)
Mar-06-26 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-25-26 08:00AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March (GlobeNewswire)
Feb-18-26 07:00AM	NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-14-26 08:04AM	NewAmsterdam Pharma CFO Teases Mid-Year PREVAIL Trial Timeline Update at Guggenheim Biotech Summit (MarketBeat)
Feb-06-26 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.99%
Feb-04-26 08:00AM	NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit (GlobeNewswire)
Jan-09-26 08:00AM	NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities (GlobeNewswire)
Jan-06-26 07:54AM	NewAmsterdam Pharma Company N.V. (NAMS) Shares Spiked by 57% in Q3 (Insider Monkey)
Jan-05-26 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
06:50PM	Loading…
Dec-12-25 06:50PM	National Presto, Garrett Motion, and More Stocks See Action From Activist Investors (Barrons.com) -5.10%
Dec-05-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-25-25 08:00AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December (GlobeNewswire)
Nov-07-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.01%
Nov-05-25 09:15AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results (GlobeNewswire)
Nov-04-25 08:20AM	Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Oct-30-25 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November (GlobeNewswire) +8.05%
Oct-29-25 10:00AM	NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-24-25 07:31AM	Enteras oral osteoporosis drug meets endpoints in Phase II trial (Clinical Trials Arena)
Oct-10-25 06:20PM	8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors (Barrons.com) +12.26%
Oct-07-25 06:04AM	NewAmsterdam Pharma Company N.V. (NAMS) Soars 5.9%: Is Further Upside Left in the Stock? (Zacks)
Sep-24-25 08:00AM	NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire)
Aug-29-25 04:30PM	Core Scientific, NewAmsterdam Pharma, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-25-25 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September (GlobeNewswire)
08:00AM	Loading…
Aug-18-25 08:00AM	NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib (GlobeNewswire)
Aug-06-25 08:30AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.70%
07:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results (GlobeNewswire)
Jul-30-25 08:25AM	NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025 (GlobeNewswire)
Jul-22-25 08:00AM	NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025 (GlobeNewswire)
Jul-16-25 09:38AM	Jefferies Remains Bullish on NewAmsterdam Pharma (NAMS) (Insider Monkey)
Jun-17-25 12:57PM	Citi initiates coverage on biotech amid improving sentiment in sector (Investing.com) -6.38%
Jun-11-25 08:06PM	NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel (Insider Monkey) -6.14%
Jun-09-25 07:00AM	NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial (GlobeNewswire)
Jun-05-25 08:00AM	NewAmsterdam Pharma to Host R&D Day on June 11, 2025 (GlobeNewswire)
May-27-25 08:00AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June (GlobeNewswire)
May-14-25 08:00AM	NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference (GlobeNewswire)
May-12-25 09:55AM	Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know (Zacks)
May-08-25 09:30AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:15AM	Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates (Zacks)
08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results (GlobeNewswire)
May-07-25 07:15AM	NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 (GlobeNewswire)
May-02-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-30-25 08:00AM	NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress (GlobeNewswire)
Apr-29-25 11:40AM	NewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
Apr-23-25 01:01PM	Is NewAmsterdam Pharma Company N.V. (NAMS) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Apr-17-25 04:01PM	NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors (GlobeNewswire)
Apr-11-25 04:23PM	NewAmsterdam Pharma (NAMS): Among Billionaire Stanley Druckenmiller's Top Stock Picks with Huge Upside Potential (Insider Monkey) +8.60%
Apr-04-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.17%
Mar-31-25 04:18PM	Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? (Investor's Business Daily) -5.93% -10.21%
08:00AM	NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-30-25 07:10AM	abrdn World Healthcare Fund Q4 2024 Commentary (Seeking Alpha)
Feb-26-25 08:00AM	NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +10.23%
Feb-25-25 08:00AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March (GlobeNewswire)
Feb-07-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-29-25 08:00AM	NewAmsterdam Pharma to Present at Guggenheim's SMID Cap Biotech Conference (GlobeNewswire)
Jan-10-25 08:00AM	NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities (GlobeNewswire)
Jan-09-25 03:38PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-13-24 05:16PM	NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-11-24 09:37PM	NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
03:06PM	NewAmsterdam Pharma Stock Hits 90-Plus RS Rating (Investor's Business Daily)
Dec-10-24 05:10PM	NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug (Investor's Business Daily) +41.41%
04:34PM	NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
07:00AM	NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
Dec-06-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-21-24 07:37AM	NewAmsterdam Pharma Reports Promising Phase 3 Trial Results (TipRanks)
Nov-20-24 04:13PM	NewAmsterdam Dives And Sacrifices A Cup Base Despite A Winning Cholesterol Study (Investor's Business Daily) -15.50%
07:00AM	NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH (GlobeNewswire)
Nov-18-24 03:20PM	NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 (GlobeNewswire)
Nov-06-24 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results (GlobeNewswire) +13.73%
Nov-01-24 05:26PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-28-24 04:30PM	NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November (GlobeNewswire)
Oct-04-24 04:30PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-06-24 04:32PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-30-24 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-07-24 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results (GlobeNewswire)
Aug-02-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.35%
Jul-29-24 08:54AM	NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations (Investor's Business Daily) -8.54%
08:00AM	NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
Jul-26-24 04:01PM	NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024 (GlobeNewswire)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jul-08-24 08:00AM	NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors (GlobeNewswire)
Jul-03-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-11-24 08:00AM	NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office (GlobeNewswire)
Jun-07-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June (GlobeNewswire)
May-21-24 08:00AM	NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings (GlobeNewswire)
May-09-24 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results (GlobeNewswire)
May-03-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-24 08:00AM	NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 (GlobeNewswire)
Apr-09-24 08:00AM	NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease (GlobeNewswire)
Apr-01-24 08:00AM	NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer (GlobeNewswire) -9.64%
Mar-25-24 08:00AM	NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress (GlobeNewswire)
Mar-13-24 01:32PM	NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up (Zacks)
Mar-12-24 08:00AM	NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD (GlobeNewswire) +11.89%

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LANGE LOUIS G	Director	Mar 11 '26	Sale	30.42	44,619	1,357,230	10,360	Mar 12 04:25 PM
Louis G. Lange	Affiliate	Mar 11 '26	Proposed Sale	31.27	44,619	1,395,236		Mar 11 04:08 PM
LANGE LOUIS G	Director	Mar 06 '26	Sale	29.41	28,186	828,950	0	Mar 10 08:58 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Mar 05 '26	Sale	30.30	104,467	3,165,350	69,302	Mar 09 08:18 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Mar 09 '26	Sale	30.29	101,409	3,071,679	69,302	Mar 09 08:18 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Mar 06 '26	Sale	30.32	94,124	2,853,840	69,302	Mar 09 08:18 PM
Louis G. Lange	Affiliate	Mar 06 '26	Proposed Sale	31.18	28,186	878,839		Mar 06 05:52 PM
Kastelein Johannes Jacob Piete	Affiliate	Mar 02 '26	Proposed Sale	31.18	300,000	9,354,000		Mar 05 04:14 PM
Davidson Michael H.	Chief Executive Officer	Mar 02 '26	Sale	33.25	443,707	14,753,258	174,144	Mar 02 06:08 PM
Michael H. Davidson	Affiliate	Mar 02 '26	Proposed Sale	35.46	443,707	15,733,850		Mar 02 04:10 PM
Davidson Michael H.	Chief Executive Officer	Feb 26 '26	Sale	33.71	183,332	6,179,974	174,144	Feb 26 09:40 PM
Davidson Michael H.	Chief Executive Officer	Feb 24 '26	Sale	36.15	64,708	2,338,943	459,859	Feb 26 09:40 PM
Davidson Michael H.	Chief Executive Officer	Feb 25 '26	Sale	35.30	58,253	2,056,174	459,859	Feb 26 09:40 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Feb 20 '26	Sale	35.31	45,481	1,605,998	53,500	Feb 24 04:40 PM
Michael H. Davidson	Affiliate	Feb 24 '26	Proposed Sale	36.17	750,000	27,127,500		Feb 24 04:22 PM
Kastelein Johannes Jacob Piete	Officer	Feb 20 '26	Proposed Sale	34.63	45,481	1,575,007		Feb 20 07:51 AM
Kooij Louise Frederika	Chief Accounting Officer	Jan 27 '26	Option Exercise	10.90	39,816	433,994	64,169	Jan 29 04:40 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 28 '26	Option Exercise	10.90	32,612	355,471	56,965	Jan 29 04:40 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 27 '26	Sale	32.62	39,816	1,298,798	24,353	Jan 29 04:40 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 28 '26	Sale	31.80	32,612	1,037,062	24,353	Jan 29 04:40 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 23 '26	Option Exercise	10.90	38,172	416,075	62,525	Jan 27 05:38 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 26 '26	Option Exercise	10.90	34,400	374,960	58,753	Jan 27 05:38 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 23 '26	Sale	33.75	38,172	1,288,345	24,353	Jan 27 05:38 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 26 '26	Sale	32.78	34,400	1,127,498	24,353	Jan 27 05:38 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 20 '26	Option Exercise	9.26	60,216	557,600	118,598	Jan 22 05:24 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 21 '26	Option Exercise	9.26	39,784	368,400	98,166	Jan 22 05:24 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 20 '26	Sale	31.96	60,216	1,924,401	58,382	Jan 22 05:24 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 21 '26	Sale	33.59	39,784	1,336,217	58,382	Jan 22 05:24 PM
Mayur Somaiya	Affiliate	Jan 20 '26	Proposed Sale	31.65	200,000	6,330,000		Jan 20 04:17 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Jan 05 '26	Sale	33.25	6,000	199,500	73,481	Jan 07 06:31 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 05 '26	Sale	33.25	2,647	88,013	12,353	Jan 07 06:27 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 05 '26	Sale	33.25	5,118	170,174	32,882	Jan 07 06:27 PM
Michael Davidson	affiliate	Jan 07 '26	Proposed Sale	35.48	11,582	410,889		Jan 07 01:19 PM
Douglas F Kling	Affiliate	Jan 06 '26	Proposed Sale	33.48	300,000	10,044,000		Jan 06 04:29 PM
Louise Kooij	affiliate	Jan 05 '26	Proposed Sale	33.25	2,647	88,012		Jan 05 03:18 PM
Johannes Kastelein	Affiliate	Jan 05 '26	Proposed Sale	33.25	6,000	199,499		Jan 05 03:04 PM
Mayur Ian Somaiya	affiliate	Jan 05 '26	Proposed Sale	33.25	5,118	170,173		Jan 05 03:03 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 23 '25	Option Exercise	10.00	75,117	751,170	90,117	Dec 29 05:14 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 26 '25	Option Exercise	10.10	43,872	443,220	58,872	Dec 29 05:14 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 24 '25	Option Exercise	10.00	26,011	260,110	41,011	Dec 29 05:14 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 23 '25	Sale	36.21	75,117	2,719,987	15,000	Dec 29 05:14 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 26 '25	Sale	35.30	43,872	1,548,682	15,000	Dec 29 05:14 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 24 '25	Sale	35.68	26,011	928,072	15,000	Dec 29 05:14 PM
Louise Kooij	Officer	Dec 23 '25	Proposed Sale	36.49	290,000	10,582,100		Dec 23 05:31 PM
Bain Capital Life Sciences Fun	Former Affiliate	Dec 02 '25	Proposed Sale	38.33	267,429	10,250,554		Dec 02 09:25 PM
BCLS II Investco, LP	Former Affiliate	Dec 02 '25	Proposed Sale	38.33	4,500,000	172,485,000		Dec 02 09:23 PM
BCIP Life Sciences Associates,	Former Affiliate	Dec 02 '25	Proposed Sale	38.33	32,571	1,248,446		Dec 02 09:22 PM
Topper James N	Director	Sep 15 '25	Buy	23.70	660	15,639	3,028,524	Sep 17 05:22 PM
Kooij Louise Frederika	Chief Accounting Officer	Sep 09 '25	Option Exercise	10.00	150,000	1,500,000	165,000	Sep 10 05:39 PM
Kooij Louise Frederika	Chief Accounting Officer	Sep 09 '25	Sale	25.83	150,000	3,874,017	15,000	Sep 10 05:39 PM
Topper James N	Director	Sep 08 '25	Buy	24.99	1,260	31,487	3,027,864	Sep 10 05:19 PM
Louise Kooij	Affiliate	Sep 09 '25	Proposed Sale	25.20	150,000	3,780,000		Sep 09 11:57 AM
Kooij Louise Frederika	Chief Accounting Officer	Sep 03 '25	Sale	25.09	18,073	453,452	15,000	Sep 05 05:06 PM
Kooij Louise Frederika	Officer	Sep 03 '25	Proposed Sale	24.05	18,073	434,656		Sep 03 08:21 AM
Kooij Louise Frederika	Chief Accounting Officer	Aug 25 '25	Sale	24.86	8,269	205,567	15,000	Aug 27 05:08 PM
Kooij Louise Frederika	Officer	Aug 25 '25	Proposed Sale	25.19	8,269	208,296		Aug 27 04:57 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Aug 22 '25	Sale	25.14	50,000	1,257,140	69,302	Aug 25 05:04 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Aug 21 '25	Sale	24.29	50,000	1,214,500	119,302	Aug 25 05:04 PM
Kastelein Johannes Jacob Piete	Officer	Aug 21 '25	Proposed Sale	25.00	100,000	2,500,000		Aug 25 05:03 PM
Topper James N	Director	Aug 11 '25	Buy	23.98	471	11,294	3,026,604	Aug 13 04:49 PM
Kling Douglas F	Chief Operating Officer	Jul 16 '25	Option Exercise	10.90	51,043	556,369	95,043	Jul 17 05:19 PM
Kling Douglas F	Chief Operating Officer	Jul 15 '25	Option Exercise	10.90	47,569	518,502	91,569	Jul 17 05:19 PM
Kling Douglas F	Chief Operating Officer	Jul 16 '25	Sale	21.10	51,043	1,077,007	44,000	Jul 17 05:19 PM
Kling Douglas F	Chief Operating Officer	Jul 15 '25	Sale	21.44	47,569	1,019,648	44,000	Jul 17 05:19 PM
NAP PoolCo B.V.	Affiliate	Jul 14 '25	Proposed Sale	21.56	1,433,193	30,899,641		Jul 14 04:12 PM
Topper James N	Director	Jun 24 '25	Buy	18.43	2,520	46,454	3,024,873	Jun 26 07:41 PM
Topper James N	Director	Jun 25 '25	Buy	18.26	1,260	23,012	3,026,133	Jun 26 07:41 PM
Kling Douglas F	Chief Operating Officer	Jun 16 '25	Option Exercise	10.20	100,000	1,019,709	144,000	Jun 18 04:50 PM
Kling Douglas F	Chief Operating Officer	Jun 16 '25	Sale	19.29	100,000	1,929,141	44,000	Jun 18 04:50 PM
Topper James N	Director	Jun 16 '25	Buy	19.50	8,584	167,381	3,022,153	Jun 18 04:42 PM
NAP PoolCo B.V.	Affiliate	Jun 16 '25	Proposed Sale	19.50	303,197	5,912,342		Jun 18 12:31 PM
LANGE LOUIS G	Director	Jun 01 '25	Option Exercise	0.00	68	0	28,186	Jun 03 04:59 PM
Kling Douglas F	Chief Operating Officer	May 15 '25	Option Exercise	10.00	100,000	1,000,000	144,000	May 19 04:44 PM
Douglas F Kling	Affiliate	May 15 '25	Proposed Sale	18.75	298,612	5,598,975		May 15 04:40 PM

Open in Screener

PHAT

Phathom Pharmaceuticals Inc

May 13 • 04:00PM ET

12.56

+0.03 0.24 %

Healthcare • Biotechnology • USA • Small • NASD

PHAT Phathom Pharmaceuticals Inc daily Stock Chart

Peers: IRWD ARDX MDGL VERA EWTX

| Held by: VTI IWM VXF XPH IBB IWN SURI SCHA VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-2.11	Insider Own	37.29%	Shs Outstand	79.44M	Perf Week	-0.87%
Market Cap	1.00B	Forward P/E	10.47	EPS next Y	1.20	Insider Trans	0.00%	Shs Float	50.02M	Perf Month	-0.87%
Enterprise Value	1.37B	PEG	-	EPS next Q	-0.20	Inst Own	48.40%	Short Float	19.47%	Perf Quarter	2.70%
Income	-157.30M	P/S	4.89	EPS this Y	82.13%	Inst Trans	4.60%	Short Ratio	7.98	Perf Half Y	-8.52%
Sales	204.89M	P/B	-	EPS next Y	321.63%	ROA	-52.49%	Short Interest	9.74M	Perf YTD	-24.29%
Book/sh	-4.24	P/C	5.54	EPS next 5Y	-	ROE	-	52W High	18.31 -31.40%	Perf Year	279.46%
Cash/sh	2.27	P/FCF	-	EPS past 3/5Y	15.64% 4.82%	ROIC	-89.08%	52W Low	3.02 315.22%	Perf 3Y	-6.69%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	84.93%	Volatility	5.71% 7.43%	Perf 5Y	-63.05%
Dividend TTM	-	EV/Sales	6.68	EPS Y/Y TTM	59.74%	Oper. Margin	-47.15%	ATR (14)	0.83	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.16	Sales Y/Y TTM	150.30%	Profit Margin	-76.77%	RSI (14)	54.88	Recom	1.30
Dividend Gr. 3/5Y	- -	Current Ratio	2.21	EPS Q/Q	71.76%	SMA20	2.33%	Beta	0.58	Target Price	23.70
Payout	-	Debt/Eq	-	Sales Q/Q	104.43%	SMA50	8.07%	Rel Volume	0.94	Prev Close	12.53
Employees	371	LT Debt/Eq	-	Earnings	Apr 30 BMO	SMA200	-1.27%	Avg Volume	1.22M	Price	12.56
IPO	Oct 25, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-27.37% 4.29%	Trades		Volume	1,151,261	Change	0.24%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-26	Upgrade	Barclays	Equal Weight → Overweight	$18
Dec-12-25	Initiated	Raymond James	Strong Buy	$28
Dec-09-25	Initiated	Barclays	Equal Weight	$16
Feb-14-25	Initiated	Cantor Fitzgerald	Overweight	$23
May-03-24	Initiated	Stifel	Buy	$24
Jan-05-24	Reiterated	Needham	Buy	$23 → $26
Aug-09-23	Initiated	H.C. Wainwright	Buy	$28
May-11-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-13-23	Initiated	Craig Hallum	Buy	$21
Oct-21-22	Initiated	Jefferies	Buy	$16
May-06-22	Downgrade	Evercore ISI	Outperform → In-line
May-12-21	Upgrade	Goldman	Sell → Neutral	$40 → $48
Feb-17-21	Initiated	BMO Capital Markets	Outperform	$63
Feb-02-21	Initiated	Guggenheim	Buy	$60
Jun-26-20	Downgrade	Goldman	Neutral → Sell	$34
Nov-20-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Needham	Buy	$40
Nov-19-19	Initiated	Jefferies	Buy	$32
Nov-19-19	Initiated	Goldman	Neutral	$32

Show Previous Ratings

May-01-26 08:00AM	Phathom Pharmaceuticals to Highlight VOQUEZNA (vonoprazan) at DDW 2026 Annual Meeting (GlobeNewswire) +7.23%
Apr-30-26 08:48PM	Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby)
06:59AM	Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-26 09:24AM	Phathom Pharmaceuticals Inc (PHAT) Q1 2026: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Apr-20-26 08:00AM	Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026 (GlobeNewswire)
08:00AM	Loading…
Apr-06-26 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-01-26 04:27AM	Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why (Insider Monkey)
Feb-27-26 08:30AM	Phathom Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby) -7.37%
04:30AM	Phathom Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
Feb-26-26 04:12PM	Phathom Pharmaceuticals Inc (PHAT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +10.06%
12:15PM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
07:00AM	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance (GlobeNewswire)
Feb-25-26 07:33AM	What To Expect From Phathom Pharmaceuticals Inc (PHAT) Q4 2025 Earnings (GuruFocus.com) +6.12%
Feb-24-26 09:40AM	Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-23-26 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Loading…
Feb-17-26 08:00AM	Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026 (GlobeNewswire) +6.16%
Feb-14-26 05:05PM	Phathom Pharmaceuticals Pivots to GI Focus, Targets 2H 2026 Profitability, CEO Says at Guggenheim Summit (MarketBeat)
Feb-05-26 08:00AM	Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 (GlobeNewswire) -6.20%
Jan-08-26 08:49AM	Phathom's Early Numbers Show Sales Strength, Eyes 2026 Profitability (Benzinga) -13.72%
05:17AM	Stock Market Today: S&P 500, Dow Jones Futures Decline - AZZ, Northrop Grumman, Immuneering In Focus (Benzinga)
Jan-07-26 10:33PM	Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +10.45%
04:05PM	Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:01PM	Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Dec-25-25 07:00PM	Raymond James Sees an Attractive Setup in These 2 Strong Buy Stocks (TipRanks)
Nov-04-25 08:00AM	Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA (vonoprazan) in Eosinophilic Esophagitis (EoE) (GlobeNewswire)
Nov-03-25 07:59AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-30-25 04:24PM	Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com)
08:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-29-25 09:49AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
09:59AM	Loading…
Oct-25-25 09:59AM	Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease (GlobeNewswire)
Oct-23-25 08:00AM	Phathom Pharmaceuticals to Highlight VOQUEZNA (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting (GlobeNewswire)
Oct-20-25 08:00AM	Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025 (GlobeNewswire) +8.10%
Oct-06-25 08:00AM	Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer (GlobeNewswire)
Sep-18-25 12:00PM	Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why (Zacks) +6.82%
Sep-08-25 05:04PM	Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High? (Zacks)
Aug-25-25 07:59AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-22-25 09:55AM	Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet (Zacks) +8.77%
Aug-20-25 08:00AM	Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing (GlobeNewswire)
Aug-07-25 08:10AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.29%
06:59AM	Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-06-25 08:25AM	MannKind (MNKD) Reports Break-Even Earnings for Q2 (Zacks)
Aug-04-25 08:15AM	Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-28-25 08:00AM	Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025 (GlobeNewswire) -8.62%
Jun-23-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.12%
07:59AM	Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Jun-16-25 08:00AM	Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets Through May 3, 2032 (GlobeNewswire)
Jun-09-25 09:55AM	Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade (Zacks)
Jun-06-25 12:45PM	Phathom Pharmaceuticals shares soar on FDA exclusivity grant (Investing.com) +90.19%
12:27PM	Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032 (GlobeNewswire)
May-15-25 07:59AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.08%
May-08-25 09:35AM	After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT) (Zacks)
May-02-25 03:02AM	Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com) -17.86%
May-01-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -21.68%
12:09PM	Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-25 07:59AM	Phathom Pharmaceuticals to Present VOQUEZNA (vonoprazan) Data at DDW 2025 Annual Meeting (GlobeNewswire)
Apr-23-25 08:00AM	Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 (GlobeNewswire)
Apr-16-25 08:00AM	Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors (GlobeNewswire) -11.43%
Apr-08-25 07:09AM	Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? (Zacks) -12.73%
Apr-03-25 11:25AM	Phathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade) (Seeking Alpha) -8.83%
08:00AM	Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -18.34% +7.23%
08:00AM	Phathom Pharmaceuticals Announces Leadership Succession (GlobeNewswire)
Mar-31-25 07:59AM	Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA (vonoprazan) (GlobeNewswire)
Mar-07-25 02:08AM	Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ... (GuruFocus.com) -14.24%
Mar-06-25 09:10AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-25 07:21AM	Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2024 Result (GuruFocus.com) +8.96%
Feb-24-25 08:00AM	Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 (GlobeNewswire) -5.82%
Jan-29-25 08:00AM	Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Dec-12-24 09:39AM	Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)? (Insider Monkey)
Dec-11-24 08:00AM	Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA (vonoprazan) Tablets (GlobeNewswire) -5.99%
Dec-06-24 09:35AM	Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround (Zacks) +5.88%
Nov-19-24 12:00PM	Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know (Zacks) +5.40%
Nov-08-24 06:02AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -8.86%
Nov-07-24 09:20AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-24 07:21AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Nov-04-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 08:00AM	Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 (GlobeNewswire) +8.29%
Oct-27-24 12:00PM	Phathom Pharmaceuticals to Present VOQUEZNA Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting (GlobeNewswire)
Aug-29-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-24 08:00AM	Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Aug-08-24 09:20AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.70%
08:00AM	Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-30-24 08:00AM	Phathom Pharmaceuticals Announces VOQUEZNA (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients (GlobeNewswire)
Jul-29-24 07:59AM	Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024 (GlobeNewswire)
Jul-18-24 08:00AM	Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults (GlobeNewswire) -7.68%
Jun-09-24 07:00AM	Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now (InvestorPlace)
Jun-07-24 06:17AM	Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze (InvestorPlace) +9.50%
May-28-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-24 08:00AM	Phathom Pharmaceuticals to Present VOQUEZNA (vonoprazan) Data at DDW 2024 Annual Meeting (GlobeNewswire)
May-13-24 11:02AM	Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 08:00AM	The 3 Best Healthcare Stocks to Buy in May 2024 (InvestorPlace) -5.60%
May-09-24 09:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-03-24 08:02AM	Stifel Starts Phathom Pharmaceuticals With Buy Rating, $24 Price Target (MT Newswires)
Apr-29-24 08:00AM	Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024 (GlobeNewswire)

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parikh Asit	Director	Jan 13 '26	Option Exercise	10.30	8,750	90,125	131,000	Jan 15 04:45 PM
Parikh Asit	Director	Dec 19 '25	Option Exercise	10.30	8,750	90,125	122,250	Dec 23 05:00 PM
Basta Steven L	President and CEO	Nov 28 '25	Option Exercise	0.00	90,000	0	131,625	Dec 02 06:45 PM
Breedlove Robert Charles	Principal Accounting Officer	Nov 03 '25	Sale	13.51	524	7,079	47,407	Nov 05 04:30 PM
Basta Steven L	President and CEO	Sep 25 '25	Option Exercise	0.00	90,000	0	90,000	Sep 26 07:03 PM
Breedlove Robert Charles	Principal Accounting Officer	Sep 05 '25	Sale	12.09	461	5,573	47,931	Sep 09 04:40 PM
Breedlove Robert Charles	Principal Accounting Officer	Jul 16 '25	Sale	8.36	1,692	14,152	48,392	Jul 18 04:05 PM
Topper James N	Director	May 21 '25	Buy	3.86	3,780	14,609	59,403	May 23 04:06 PM
Topper James N	Director	May 14 '25	Buy	3.32	6,300	20,919	55,623	May 15 04:17 PM

NAMS

NewAmsterdam Pharma Company NV

PHAT

Phathom Pharmaceuticals Inc

Upgrade your Finviz experience